RUA Life Sciences (AOHA) Ratios
RUA Life Sciences Ratios
DE:AOHA's free cash flow for Q4 2025 was $2.00K. For the 2025 fiscal year, DE:AOHA's free cash flow was decreased by $-27.00K and operating cash flow was $29.00K. See a summary of the company’s cash flow.
| Ratios | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.91 | 9.01 | 5.20 | 8.23 | 6.67 |
| Quick Ratio | 4.23 | 8.81 | 5.00 | 7.99 | 6.59 |
| Cash Ratio | 3.24 | 7.10 | 3.58 | 5.80 | 5.73 |
| Solvency Ratio | 0.23 | -1.09 | -1.68 | -1.68 | -0.71 |
| Operating Cash Flow Ratio | -0.20 | -2.40 | -2.84 | -4.62 | -1.29 |
| Short-Term Operating Cash Flow Coverage | -0.94 | -42.84 | -40.48 | -102.65 | -61.87 |
| Net Current Asset Value | $ 3.55M | $ 4.01M | $ 1.17M | $ 3.17M | $ 5.68M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.11 | 0.05 | 0.08 | 0.05 | 0.04 |
| Debt-to-Equity Ratio | 0.14 | 0.05 | 0.10 | 0.05 | 0.05 |
| Debt-to-Capital Ratio | 0.12 | 0.05 | 0.09 | 0.05 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.02 | 0.03 | 0.03 | 0.03 |
| Financial Leverage Ratio | 1.27 | 1.14 | 1.21 | 1.16 | 1.19 |
| Debt Service Coverage Ratio | 1.67 | -8.71 | -36.20 | -56.32 | -17.21 |
| Interest Coverage Ratio | 0.00 | -23.34 | -144.13 | -294.00 | -41.77 |
| Debt to Market Cap | 0.03 | 0.06 | 0.02 | 0.02 | 0.01 |
| Interest Debt Per Share | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 |
| Net Debt to EBITDA | -6.33 | 2.25 | 0.52 | 1.28 | 4.60 |
| Profitability Margins | |||||
| Gross Profit Margin | 77.12% | 78.32% | 65.76% | 64.31% | 64.14% |
| EBIT Margin | -0.49% | -88.41% | -106.06% | -144.55% | -101.51% |
| EBITDA Margin | 9.75% | -71.79% | -89.40% | -125.48% | -83.70% |
| Operating Profit Margin | -24.05% | -88.41% | -105.83% | -144.74% | -117.54% |
| Pretax Profit Margin | -0.24% | -92.20% | -106.56% | -145.23% | -104.32% |
| Net Profit Margin | 0.02% | -65.72% | -91.92% | -127.20% | -94.96% |
| Continuous Operations Profit Margin | -0.51% | -65.72% | -91.92% | -127.20% | -94.96% |
| Net Income Per EBT | -10.00% | 71.29% | 86.26% | 87.58% | 91.03% |
| EBT Per EBIT | 1.01% | 104.28% | 100.69% | 100.34% | 88.75% |
| Return on Assets (ROA) | 0.01% | -17.63% | -35.37% | -27.10% | -14.29% |
| Return on Equity (ROE) | 0.01% | -20.05% | -42.77% | -31.39% | -17.06% |
| Return on Capital Employed (ROCE) | -12.13% | -25.44% | -43.93% | -33.06% | -19.83% |
| Return on Invested Capital (ROIC) | -11.58% | -17.86% | -37.12% | -28.70% | -17.93% |
| Return on Tangible Assets | 0.01% | -19.33% | -43.63% | -31.79% | -15.64% |
| Earnings Yield | 0.01% | -49.03% | -17.53% | -19.01% | -5.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.77 | 4.12 | 3.71 | 1.45 | 3.17 |
| Payables Turnover | 1.38 | 3.39 | 17.35 | 3.14 | 2.09 |
| Inventory Turnover | 1.25 | 4.24 | 9.21 | 4.68 | 6.45 |
| Fixed Asset Turnover | 1.30 | 0.89 | 0.80 | 0.63 | 0.78 |
| Asset Turnover | 0.44 | 0.27 | 0.38 | 0.21 | 0.15 |
| Working Capital Turnover Ratio | 0.94 | 0.71 | 0.80 | 0.33 | 0.37 |
| Cash Conversion Cycle | 124.45 | 67.11 | 117.09 | 213.18 | -2.89 |
| Days of Sales Outstanding | 96.91 | 88.63 | 98.49 | 251.57 | 115.00 |
| Days of Inventory Outstanding | 292.47 | 86.06 | 39.63 | 78.03 | 56.61 |
| Days of Payables Outstanding | 264.93 | 107.58 | 21.04 | 116.42 | 174.51 |
| Operating Cycle | 389.37 | 174.69 | 138.13 | 329.60 | 171.62 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.04 | -0.05 | -0.11 | -0.08 |
| Free Cash Flow Per Share | -0.00 | -0.04 | -0.07 | -0.15 | -0.12 |
| Dividend Paid and CapEx Coverage Ratio | -3.53 | -24.15 | -2.61 | -2.61 | -2.30 |
| Capital Expenditure Coverage Ratio | -3.53 | -24.15 | -2.61 | -2.61 | -2.30 |
| Operating Cash Flow Coverage Ratio | -0.21 | -3.41 | -2.47 | -6.86 | -3.47 |
| Operating Cash Flow to Sales Ratio | -0.05 | -0.61 | -0.54 | -1.45 | -0.93 |
| Free Cash Flow Yield | -3.77% | -47.09% | -14.21% | -30.04% | -8.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 7447.23 | -2.04 | -5.70 | -5.26 | -17.26 |
| Price-to-Sales (P/S) Ratio | 1.81 | 1.34 | 5.24 | 6.69 | 16.39 |
| Price-to-Book (P/B) Ratio | 1.02 | 0.41 | 2.44 | 1.65 | 2.94 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -26.50 | -2.12 | -7.04 | -3.33 | -12.26 |
| Price-to-Operating Cash Flow Ratio | -34.01 | -2.21 | -9.73 | -4.60 | -17.60 |
| Price-to-Earnings Growth (PEG) Ratio | -74.47 | 0.04 | 1.83 | -0.39 | -0.36 |
| Enterprise Value Multiple | 12.24 | 0.38 | -5.35 | -4.05 | -14.98 |
| Enterprise Value | 4.91M | -604.94K | 10.42M | 8.25M | 19.16M |
| EV to EBITDA | 12.24 | 0.38 | -5.35 | -4.05 | -14.98 |
| EV to Sales | 1.19 | -0.28 | 4.78 | 5.08 | 12.54 |
| EV to Free Cash Flow | -17.47 | 0.44 | -6.42 | -2.53 | -9.38 |
| EV to Operating Cash Flow | -22.42 | 0.46 | -8.87 | -3.49 | -13.46 |
| Tangible Book Value Per Share | 0.11 | 0.19 | 0.16 | 0.25 | 0.43 |
| Shareholders’ Equity Per Share | 0.12 | 0.21 | 0.21 | 0.30 | 0.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -1.10 | 0.29 | 0.14 | 0.12 | 0.09 |
| Revenue Per Share | 0.07 | 0.07 | 0.10 | 0.07 | 0.09 |
| Net Income Per Share | 0.00 | -0.04 | -0.09 | -0.09 | -0.08 |
| Tax Burden | -0.10 | 0.71 | 0.86 | 0.88 | 0.91 |
| Interest Burden | 0.50 | 1.04 | 1.00 | 1.00 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.40 | 0.50 | 0.57 | 0.38 |
| SG&A to Revenue | 1.01 | 0.52 | 0.50 | 0.81 | 1.84 |
| Stock-Based Compensation to Revenue | 0.03 | -0.02 | 0.05 | 0.09 | 0.08 |
| Income Quality | -219.00 | 0.92 | 0.59 | 1.14 | 0.98 |
Currency in GBP